Education
About Us
Working with TipRanks
Follow Us
Biocardia (BCDA)
:BCDA
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.5Last Year’s EPS
-0.88Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: -21.30%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and regulatory preparation, emphasizing the potential impact of BioCardia's therapies. However, financial challenges, including increased expenses and limited cash reserves, present ongoing challenges.Company Guidance
During BioCardia's first quarter 2025 earnings call, the company provided several key metrics and strategic focuses. The CardiAMP Heart Failure Trial demonstrated safety and meaningful benefits, targeting a significant clinical need for approximately 1 million Americans with heart failure, who have a 10% mortality rate per year. The company's primary focus for the second quarter is to present this data to regulatory bodies, including the FDA and Japan's PMDA, and to further engage the clinical community. The CardiAMP Heart Failure II Trial is actively enrolling at three sites, with plans for full enrollment over the next two years. Financially, total expenses rose to $2.7 million from $2.3 million year-over-year, driven by increased R&D expenses, which rose to $1.5 million due to the wrap-up of the initial trial and the initiation of the second trial. The company ended the quarter with $949,000 in cash and cash equivalents, following a modest financing to support milestones and manage a net loss of $2.7 million.Successful CardiAMP Heart Failure Trial
The CardiAMP Heart Failure Trial demonstrated safety and meaningful benefits for heart failure patients, potentially addressing a significant unmet clinical need for approximately 1 million Americans.
New Trial Enrollments and Progress
The CardiAMP Heart Failure II Trial is actively enrolling patients at three clinical sites with plans to be fully enrolled over the next two years, aiming to confirm previous results and enhance enrollment.
Data Safety Monitoring Board Review Success
The CardiALLO allogeneic mesenchymal stem cell therapy for ischemic heart failure passed a Data Safety Monitoring Board review, with no adverse events in the low-dose cohort.
Helix Biotherapeutic Delivery System Advances
Preparation for submission for approval of the Helix biotherapeutic delivery system is underway, with potential to be the first approved transendocardial biotherapeutic delivery system in the U.S.
Approval of Morph DNA Platform
The FDA approved the Morph DNA steerable introducer platform, which is being positively received by physicians.
BCDA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BCDA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | $2.77 | $2.32 | -16.25% |
Mar 26, 2025 | $2.55 | $2.68 | +5.10% |
Nov 13, 2024 | $2.35 | $2.02 | -14.04% |
Aug 13, 2024 | $2.64 | $2.59 | -1.89% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Biocardia (BCDA) report earnings?
Biocardia (BCDA) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Biocardia (BCDA) earnings time?
Biocardia (BCDA) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BCDA EPS forecast?
BCDA EPS forecast for the fiscal quarter 2025 (Q2) is -0.5.